EUVIMEDEUVIMED entdecken
Crossref

Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy

Mohammed M Alruwaili, Yanqi Guo, Justin Zonneville, Thomas Melendy, Robert M Straubinger, Barbara A Foster, Priyanka Rajan, Henry Withers, Sarah Chatley, Renuka Iyer, Christos Fountzilas, Andrei V Bakin

Cancer Letters · 2026-11 · 218962

DOI: 10.1016/j.canlet.2026.218962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-11. Verfasst von Mohammed M Alruwaili und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263; Department of Medical Laboratory Techn…. Die Arbeit nennt 40 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Existing treatment options for colorectal and pancreatic cancers harboring mutant p53 (p53mut) are largely ineffective and lack selectivity. Our novel therapeutic strategy for p53mut cancers with a thymidine analogue (TAS102) and a PARP inhibitor (PARPi) showed promising efficacy in a clinical trial, although the mechanisms remain not fully understood. Here, we investigated the molecular mechanisms underlying therapeutic efficacy of our approach and explored new combinations to further enhance the response. To define the contribution of each drug into the therapeutic response, we conducted an unbiased transcriptomic analysis in p53-proficient and p53mut cancer models. The biological effects were investigated in comprehensive analyses of cell proliferation, cell death, and DNA damage. The drug interactions were explored in cytotoxicity assays and efficacy was tested in patient-derived colorectal and pancreatic cancer models. We found that TAS102-PARPi treatment induces DNA breaks and long G2-arrest in p53mut cells, whereas normal cells rapidly repair their DNA and re-enter the cell cycle. Transcriptomic analysis showed that TAS102 is the major driver of the response, whereas PARPi improves selectivity of the TAS102 effects. The treatment does not block replication in p53mut cells but induces post-replicative DNA repair and represses mitosis. Delayed blockade of G2-checkpoint results in massive cell death in p53mut cells selectively. Priming TAS102-PARPi treatment in combination with delayed G2-checkpoint blockade was highly effective against cancer models and was well-tolerated in mice. Broadly, a novel two-step therapeutic strategy showed high efficacy and selectivity for p53mut cancers and low toxicity to normal tissues, demonstrating potential for clinical translation.

Schlagwörter

Stichwörter der Autor:innen

TAS102colorectal cancerpancreatic cancerpoly (ADP-ribose) polymerase inhibitortrifluorothymidine

Autor:innen und Institutionen

  • Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263; Department of Medical Laboratory Technology, College of Applied Medical Science, Northern Border University,…
  • Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263.
  • Department of Microbiology and Immunology, University at Buffalo, 14214.
  • Department of Pharmaceutical Sciences, University at Buffalo, 14214; Department of Pharmacology and Therapeutics.
  • Department of Pharmacology and Therapeutics.
  • Department of Biostatistics and Bioinformatics.

Förderung

  • NCI NIH HHS

Zitieren

APA

Alruwaili, M. M., Guo, Y., Zonneville, J., Melendy, T., Straubinger, R. M., Foster, B. A., Rajan, P., Withers, H., Chatley, S., Iyer, R., Fountzilas, C., & Bakin, A. V. (2026). Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy. Cancer Letters, 218962. https://doi.org/10.1016/j.canlet.2026.218962

Vancouver

Alruwaili MM, Guo Y, Zonneville J, Melendy T, Straubinger RM, Foster BA, et al. Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy. Cancer Letters. 2026:218962. doi:10.1016/j.canlet.2026.218962

BibTeX
@article{Alruwaili2026,
  author = {Alruwaili, Mohammed M and Guo, Yanqi and Zonneville, Justin and Melendy, Thomas and Straubinger, Robert M and Foster, Barbara A and Rajan, Priyanka and Withers, Henry and Chatley, Sarah and Iyer, Renuka and Fountzilas, Christos and Bakin, Andrei V},
  title = {Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy},
  journal = {Cancer Letters},
  year = {2026},
  pages = {218962},
  doi = {10.1016/j.canlet.2026.218962}
}
Kostenlos starten →